SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the
company is scheduled to present a corporate overview at two
upcoming investor conferences at The Waldorf Astoria in
New York City:
- 16th Annual BIO CEO & Investor
Conference
Presentation: February 11,
2014, at 9:30 a.m. Eastern
Time (6:30 a.m. Pacific
Time)
- 2014 Leerink Global Healthcare Conference
Presentation: February 12, 2014, at
1:50 p.m. Eastern Time (10:50 a.m. Pacific Time)
A live audio webcast of each presentation will be available
under the investor relations section of Arena's website at
www.arenapharm.com. A replay of each presentation will be available
for 30 days following the event. Please connect to Arena's website
several minutes prior to the start of the webcast to ensure
adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a biopharmaceutical company focused on discovering,
developing and commercializing novel drugs that target G
protein-coupled receptors, or GPCRs, to address unmet medical
needs. BELVIQ® (lorcaserin HCl), Arena's internally
discovered drug, is approved for marketing in the United States, and is under review for
regulatory approval in additional territories. Arena's US
operations are located in San Diego,
California, and its operations outside of the United States, including its commercial
manufacturing facility, are located in Zofingen, Switzerland. For more information, visit
Arena's website at www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are
registered service marks of Arena Pharmaceuticals, Inc.
BELVIQ® is a registered trademark of Arena
Pharmaceuticals GmbH.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about the marketing,
regulatory review and approval of BELVIQ; and Arena's focus, plans,
goals, strategy, expectations, research and development programs,
and ability to discover and develop compounds and commercialize
drugs. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include, but are not limited to, the
following: risks related to commercializing drugs, including
regulatory, manufacturing, supply and marketing issues and the
availability and use of BELVIQ; cash and revenues generated from
BELVIQ, including the impact of competition; Arena's revenues will
be based in part on estimates, judgment and accounting policies,
and incorrect estimates or disagreement regarding estimates or
accounting policies may result in changes to Arena's guidance or
previously reported results; the timing and outcome of regulatory
review is uncertain, and BELVIQ may not be approved for marketing
when expected or ever in combination with another drug, for another
indication or using a different formulation or in any other
territory for any indication; regulatory decisions in one territory
may impact other regulatory decisions and Arena's business
prospects; government and commercial reimbursement and pricing
decisions; risks related to relying on collaborative arrangements;
the timing and receipt of payments and fees, if any, from
collaborators; the entry into or modification or termination of
collaborative arrangements; unexpected or unfavorable new data;
nonclinical and clinical data is voluminous and detailed, and
regulatory agencies may interpret or weigh the importance of data
differently and reach different conclusions than Arena or others,
request additional information, have additional recommendations or
change their guidance or requirements before or after approval;
data and other information related to any of Arena's research and
development may not meet regulatory requirements or otherwise be
sufficient for further research and development, regulatory review
or approval or continued marketing; Arena's ability to obtain and
defend patents; the timing, success and cost of Arena's research
and development; results of clinical trials and other studies are
subject to different interpretations and may not be predictive of
future results; clinical trials and other studies may not proceed
at the time or in the manner expected or at all; having adequate
funds; and satisfactory resolution of litigation or other
disagreements with others. Additional factors that could cause
actual results to differ materially from those stated or implied by
Arena's forward-looking statements are disclosed in Arena's filings
with the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact: Arena
Pharmaceuticals, Inc.
Cindy McGee, Vice
President,
Investor Relations
& Alliance Management
cmcgee@arenapharm.com
858.453.7200, ext.
1479
|
Media Contact: Russo
Partners
David Schull,
President
david.schull@russopartnersllc.com
858.717.2310
|
SOURCE Arena Pharmaceuticals, Inc.